On February 19th, 2014 Health Canada issued an information update regarding labeling changes in the fosamprenavir (Telzir™) product monograph. The update includes a strengthened warning to avoid co-administration of fosamprenavir with certain medications used for regulating the rhythm of the heart. This labeling change does not represent a new safety concern.
For more information: Click here to view the Health Canada advisory